Skip to main content
NewslettersWatchlist

Schrodinger Inc(SDGR-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low23.36
Day High24.27
Open:23.60
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Barchart
6 Under-the-Radar AI Stocks That Analysts Expect to Rally
Motley Fool
Billionaire Bill Gates Has 35% of His Portfolio Invested in These 2 Artificial Intelligence (AI) Stocks: Are They No-Brainer Buys?
Motley Fool
These Are the 3 Hottest Biopharma Trends of 2024. Should You Invest?
Motley Fool
Is Schrödinger Stock a Buy Now?
Motley Fool
This Artificial Intelligence (AI) Stock Is Powering the Biotech Revolution: Should You Invest?
Motley Fool
Why Wall Street Thinks This Artificial Intelligence (AI) Stock Could Skyrocket 140% Over the Next 12 Months
Motley Fool
3 Artificial Intelligence (AI) Stocks That Could Soar More Than Nvidia, According to Wall Street
Motley Fool
3 AI Drug Discovery Stocks to Watch
Motley Fool
Here's Bill Gates' Top Artificial Intelligence Stock Other Than Microsoft -- and Wall Street Thinks It Can Soar Nearly 70% Over the Next 12 Months
Motley Fool
Every AI Stock Cathie Wood Owns, Ranked From Best to Worst
Motley Fool
Why Shares of Schrödinger Are Falling Thursday
MarketBeat
Here are 3 AI Drug Discovery Stocks to Put on Your Watchlist
MarketBeat
Biotech & Healthcare Meet AI: Stocks Soar On Innovation Potential
MarketBeat
Exscientia is the Sniper of the AI Drug Discovery Industry
Motley Fool
3 Cutting-Edge Biotech Stocks That Are Riding the AI Wave Like None Other
Motley Fool
Better AI Biotech Stock: Schrödinger vs. Recursion Pharmaceuticals
Motley Fool
This Artificial Intelligence Biotech Stock Is Crushing the Market, but Is It a Buy?
MarketBeat
Nvidia Invested $50 million into This AI Drug Discovery Biotech
Motley Fool
Why Shares of Schrödinger Rose This Week
Motley Fool
3 Key Biotech Trends for 2023 And Beyond
Motley Fool
Why Investors Should Keep an Eye on These 3 AI Start-Ups, Including UiPath and C3.ai
Business Wire
Schrödinger Reports Strong First Quarter 2023 Financial Results
Business Wire
Schrödinger Publishes Inaugural Corporate Sustainability Report
Business Wire
Schrödinger to Announce First Quarter 2023 Financial Results on May 4
Business Wire
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Business Wire
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Motley Fool
Not Quite a Bailout: So Much Banking News to Discuss
MarketBeat
MarketBeat Week in Review – 3/6 - 3/10
MarketBeat
Schrodinger is an AI-Powered Drug Discovery Developer to Watch
Motley Fool
Why Shares of Schrödinger Were Up Today
Business Wire
Schrödinger Reports Strong Fourth Quarter and Full-Year 2022 Financial Results
Business Wire
Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Profile

Schr'dinger Inc. provides computational platforms to accelerate drug discovery and materials design deployed by biopharmaceutical and industrial companies, academic institutions and government laboratories. Schr'dinger Inc. is based in NEW YORK.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.